ATLASDiaMedica Therapeutics (DMAC) earnings date: Nov 11, 2026
DiaMedica Therapeutics (DMAC) reports earnings for the quarter ended Sep 30, 2026 on Wed, Nov 11, 2026, after the close. Analysts expect EPS of -$0.20.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on DMAC
| Last price | $9.25 (-2.8%) |
|---|---|
| Normal 1-day range (±1σ) | ±4.1% |
| Earnings beat history | Beat the EPS estimate in 3 of the last 4 reports |
These figures come from the same calibrated model and valuation as the DiaMedica Therapeutics stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
DiaMedica Therapeutics reports on Nov 11, 2026. One email the day before, with ATLAS’s read on DiaMedica Therapeutics. You can switch it off at any time.
Alert me before DMAC reportsFree to start. Creating an account takes under a minute.
DMAC earnings at a glance
| Next report (confirmed) | Wed, Nov 11, 2026 |
|---|---|
| Time | After the close |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$0.20 |
| Last report | Aug 10, 2026 · Beat |
| Beat rate (last 4 reports) | 3 of 4 (75%) |
| Average EPS surprise | +5.3% |
| Average move around a report | ±2.2% (last 4) |
| Sector | Healthcare · Biotechnology |
DiaMedica Therapeutics earnings history: last 4 reports
DiaMedica Therapeutics last reported on Aug 10, 2026: EPS of -$0.19 against an estimate of -$0.20 (+5.0% surprise), a beat.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 10, 2026 | -$0.20 | -$0.19 | +5.0% | Beat | +1.8% |
| May 6, 2026 | -$0.18 | -$0.19 | -5.6% | Miss | +4.5% |
| Mar 30, 2026 | -$0.18 | -$0.17 | +5.6% | Beat | -0.3% |
| Jan 23, 2026 | $1.61 | $1.87 | +16.2% | Beat | +2.3% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for DMAC
See the fair value, the probability range and the earnings history of DiaMedica Therapeutics on its ATLAS page.
DiaMedica Therapeutics (DMAC) stock analysisPlans from €3.99 a month.
DiaMedica Therapeutics earnings: frequently asked questions
When does DiaMedica Therapeutics (DMAC) report earnings?
DiaMedica Therapeutics is scheduled to report on Wednesday, November 11, 2026, after the close. ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for DMAC?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$0.20 per share (USD). Estimates can change before the report.
How often does DMAC beat earnings estimates?
Of its last 4 reports with a recorded result, DiaMedica Therapeutics beat the EPS estimate 3 times; the average surprise was +5.3%. Past results do not predict the next one.
How much does DMAC move around earnings?
Over its last 4 reports the stock moved an average of 2.2% (absolute, from the close before the report day to the close after it), and finished higher 3 of 4 times.
Did DiaMedica Therapeutics beat earnings estimates last quarter?
DiaMedica Therapeutics last reported on Aug 10, 2026: EPS of -$0.19 against an estimate of -$0.20 (+5.0% surprise), a beat.
How much does DMAC usually move in a day?
On a normal trading day the ATLAS model puts DMAC’s one-day range at about ±4.1%, with a 49% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Wed, Nov 11, 2026
Educational information, not investment advice. Disclaimer